Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease (ENTERPRISE)
patients will be taking part in this study
Drug: Vedolizumab Drug: Placebo
GI Research Institute
Suite 770-1190 Hornby Street, Vancouver, British Columbia, Canada
The purpose of this study is to evaluate perianal fistula healing at Week 30 in 2 different dose regimens of vedolizumab intravenous (IV) 300 milligram (mg) in participants with fistulizing Crohn's disease (CD).